Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (41-50 of 436) with videos related to

Pageof 44
Sort By:
The Urologic Clinics of North America|December 19, 2003
Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groupsManish I Patel, Robert J Motzer, Joel Sheinfeld
Seminars in Oncology|August 27, 2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancerAna M Molina, Robert J Motzer, Daniel Y Heng
The Urologic Clinics of North America|November 29, 2015
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell CarcinomaAndrew G Winer, Robert J Motzer, A Ari Hakimi
Hematology/Oncology Clinics of North America|July 19, 2011
mTOR inhibitors in advanced renal cell carcinomaMartin H Voss, Ana M Molina, Robert J Motzer
Expert Review of Anticancer Therapy|August 3, 2011
High-dose chemotherapy and stem cell transplantation for advanced testicular cancerMartin H Voss, Darren R Feldman, Robert J Motzer
Medical Oncology (Northwood, London, England)|August 11, 2010
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinibAna M Molina, Michelle S Ginsberg, Robert J Motzer
Current Opinion in Urology|July 27, 2019
The current role for adjuvant and neoadjuvant therapy in renal cell cancerJack P Gleeson, Robert J Motzer, Chung-Han Lee
Oncology (Williston Park, N.Y.)|January 4, 2018
Optimizing Treatment Approaches in Advanced Renal CancerJuan C Osorio, Robert J Motzer, Martin H Voss
The New England Journal of Medicine|July 5, 2018
Immune Checkpoint Blockade in Advanced Renal-Cell CarcinomaRobert J Motzer, M Brent McHenry, Allen C Chen
Cancer|November 19, 2009
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretationSujata Patil, Nicole Ishill, John Deluca, et al.
Pageof 44

Showing results (41-50 of 436) with videos related to

Sort By:
Pageof 44
The Urologic Clinics of North America|December 19, 2003
Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groupsManish I Patel, Robert J Motzer, Joel Sheinfeld
Seminars in Oncology|August 27, 2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancerAna M Molina, Robert J Motzer, Daniel Y Heng
The Urologic Clinics of North America|November 29, 2015
Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell CarcinomaAndrew G Winer, Robert J Motzer, A Ari Hakimi
Hematology/Oncology Clinics of North America|July 19, 2011
mTOR inhibitors in advanced renal cell carcinomaMartin H Voss, Ana M Molina, Robert J Motzer
Expert Review of Anticancer Therapy|August 3, 2011
High-dose chemotherapy and stem cell transplantation for advanced testicular cancerMartin H Voss, Darren R Feldman, Robert J Motzer
Medical Oncology (Northwood, London, England)|August 11, 2010
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinibAna M Molina, Michelle S Ginsberg, Robert J Motzer
Current Opinion in Urology|July 27, 2019
The current role for adjuvant and neoadjuvant therapy in renal cell cancerJack P Gleeson, Robert J Motzer, Chung-Han Lee
Oncology (Williston Park, N.Y.)|January 4, 2018
Optimizing Treatment Approaches in Advanced Renal CancerJuan C Osorio, Robert J Motzer, Martin H Voss
The New England Journal of Medicine|July 5, 2018
Immune Checkpoint Blockade in Advanced Renal-Cell CarcinomaRobert J Motzer, M Brent McHenry, Allen C Chen
Cancer|November 19, 2009
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretationSujata Patil, Nicole Ishill, John Deluca, et al.
Pageof 44